Login / Signup

A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species.

Guoju HongZhenqiu ChenXiaorui HanLin ZhouFengxiang PangRishana WuYingshan ShenXiaoming HeZhi-Nan HongZiqi LiWei HeQiu-Shi Wei
Published in: Clinical and translational medicine (2022)
Rob inhibits the activation of osteoclasts by targeting RANKL and is therefore a potential osteoporosis drug.
Keyphrases
  • bone loss
  • reactive oxygen species
  • postmenopausal women
  • bone mineral density
  • nuclear factor
  • signaling pathway
  • human health
  • emergency department
  • drug induced
  • immune response